Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Progression in Nanocarrier based Techniques to Address Fungal Infections and Patent Status in Drug Development Process

Author(s): Ravi Pratap Singh, Raj Kumar Narang and Amrinder Singh*

Volume 19, Issue 2, 2025

Published on: 22 September, 2023

Page: [183 - 204] Pages: 22

DOI: 10.2174/1872210517666230727090314

Price: $65

Abstract

Fungal infections are becoming one of the most common diseases in recent years, especially when it comes about dealing skin infections. Different drugs are available commercially with antifungal activity for topical application and are effective for treatment of mild to moderate fungal infections. However they lack dermal bioavailability due to their poor penetrability, and less retention at the site thereby resulting in poor efficacy. The remaining systemic treatment options available so far may cause adverse drug effects and many other complications. In recent years nano carrier based formulations promised to overcome the limitations of the conventional topical dosage forms. Lipid based nano carriers and their importance for potential use in delivery of antifungal agents for the treatment of superficial fungal infections have been well discussed in this review article. It comprises of different nano lipid systems involved in treatment of topical fungal infections, effect of different polymers on their size, stability, and their mechanistic action behind skin penetration and dermal retention of drug into deeper epidermal layers is also highlighted to depict recent efforts of researchers in this context. Further, addressing of the disease by novel drug delivery systems for the efficacious treatment, status of clinical trials, novel commercial formulations available for use in dermal drug delivery and patents claimed/granted in the respective fields have been discussed in detail.

Keywords: Fungal infections, pathophysiology, NDDS, commercial nanocarrier formulations, skin infections, dermal drug delivery.

« Previous Next »
Graphical Abstract

[1]
Mosallam S, Albash R, Abdelbari MA. Advanced vesicular systems for antifungal drug delivery. AAPS PharmSciTech 2022; 23(6): 206.
[http://dx.doi.org/10.1208/s12249-022-02357-y] [PMID: 35896903]
[2]
Abrigach F, Rokni Y, Takfaoui A, et al. In vitro screening, homology modeling and molecular docking studies of some pyrazole and imidazole derivatives. Biomed Pharmacother 2018; 103: 653-61.
[http://dx.doi.org/10.1016/j.biopha.2018.04.061] [PMID: 29679907]
[3]
Asadi P, Mehravaran A, Soltanloo N, Abastabar M, Akhtari J. Nanoliposome-loaded antifungal drugs for dermal administration: A review. Curr Med Mycol 2021; 7(1): 71-8.
[http://dx.doi.org/10.18502/cmm.7.1.6247] [PMID: 34553102]
[4]
Lengert EV, Talnikova EE, Tuchin VV, Svenskaya YI. Prospective nanotechnology-based strategies for enhanced intra- and transdermal delivery of antifungal drugs. Skin Pharmacol Physiol 2020; 33(5): 261-9.
[http://dx.doi.org/10.1159/000511038] [PMID: 33091913]
[5]
Manju N, Malkiet K. Nanomaterials for skin antifungal therapy: An updated review. J Appl Pharm Sci 2021; 11(1): 15-25.
[http://dx.doi.org/10.7324/JAPS.2021.11s102]
[6]
Nene S, Shah S, Rangaraj N, Mehra NK, Singh PK, Srivastava S. Lipid based nanocarriers: A novel paradigm for topical antifungal therapy. J Drug Deliv Sci Technol 2021; 62: 102397.
[http://dx.doi.org/10.1016/j.jddst.2021.102397]
[7]
Martinez-Rossi NM, Peres NTA, Bitencourt TA, Martins MP, Rossi A. State-of-the-art dermatophyte infections: Epidemiology aspects, pathophysiology, and resistance mechanisms. J Fungi 2021; 7(8): 629.
[http://dx.doi.org/10.3390/jof7080629] [PMID: 34436168]
[8]
Baldo A, Monod M, Mathy A, et al. Mechanisms of skin adherence and invasion by dermatophytes. Mycoses 2012; 55(3): 218-23.
[http://dx.doi.org/10.1111/j.1439-0507.2011.02081.x] [PMID: 21831104]
[9]
Vermout S, Tabart J, Baldo A, Mathy A, Losson B, Mignon B. Pathogenesis of dermatophytosis. Mycopathologia 2008; 166(5-6): 267-75.
[http://dx.doi.org/10.1007/s11046-008-9104-5] [PMID: 18478361]
[10]
USFDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf (accessed 18-11-2022).
[11]
USFDA.. Isavuconazonium. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207500s008,207501s007lbl.pdf (accessed 18-11-2022).
[12]
USFDA. Efinaconazole. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf (accessed 18-11-2022).
[13]
USFDA. Tavaborale. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf (acessed 11-01-2023).
[14]
USFDA Tolsura. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208901Orig1s000Approv.pdf (acessed 11-01-2023).
[15]
Available from: accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf (acessed 11-01-2023).
[16]
FDA internet application site. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf (acessed 11-01-2023).
[17]
VIVJOA™ (oteseconazole) capsules, for oral use Initial U.S. Approval. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf (acessed 11-01-2023).
[18]
Swann G. Editorial. J Vis Commun Med 2010; 33(4): 148-9.
[http://dx.doi.org/10.3109/17453054.2010.525439] [PMID: 21087182]
[19]
Someya T, Amagai M. Toward a new generation of smart skins. Nat Biotechnol 2019; 37(4): 382-8.
[http://dx.doi.org/10.1038/s41587-019-0079-1] [PMID: 30940942]
[20]
Venus M, Waterman J, McNab I. Basic physiology of the skin. Surgery 2010; 28(10): 469-72.
[http://dx.doi.org/10.1016/j.mpsur.2010.07.011]
[21]
Bragazzi N, Sellami M, Salem I, et al. Fasting and its impact on skin anatomy, physiology, and physiopathology: A comprehensive review of the literature. Nutrients 2019; 11(2): 249.
[http://dx.doi.org/10.3390/nu11020249] [PMID: 30678053]
[22]
Bangham AD. Surrogate cells or trojan horses. The discovery of liposomes. BioEssays 1995; 17(12): 1081-8.
[http://dx.doi.org/10.1002/bies.950171213] [PMID: 8634070]
[23]
Mezei M, Gulasekharam V. Liposomes—A selective drug delivery system for the topical route of administration: Gel dosage form. J Pharm Pharmacol 2011; 34(7): 473-4.
[http://dx.doi.org/10.1111/j.2042-7158.1982.tb04767.x] [PMID: 6126554]
[24]
Sharma Y, Patel P, Kurmi BD. A mini-review on new developments in nanocarriers and polymers for ophthalmic drug delivery strategies. Curr Drug Deliv 2023; 20: 1-21.
[PMID: 37143264]
[25]
Alomrani AH, Shazly GA, Amara AA, Badran MM. Itraconazole-hydroxypropyl-β-cyclodextrin loaded deformable liposomes: In vitro skin penetration studies and antifungal efficacy using Candida albicans as model. Colloids Surf B Biointerfaces 2014; 121: 74-81.
[http://dx.doi.org/10.1016/j.colsurfb.2014.05.030] [PMID: 24937135]
[26]
Pandit J, Garg M, Jain NK. Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. J Liposome Res 2014; 24(2): 163-9.
[http://dx.doi.org/10.3109/08982104.2013.871025] [PMID: 24479833]
[27]
Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005; 59(3): 485-90.
[http://dx.doi.org/10.1016/j.ejpb.2004.09.006] [PMID: 15760729]
[28]
Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2014; 21(2): 87-100.
[http://dx.doi.org/10.3109/10717544.2013.838077] [PMID: 24156390]
[29]
Ashtikar M, Nagarsekar K, Fahr A. Transdermal delivery from liposomal formulations: Evolution of the technology over the last three decades. J Control Release 2016; 242: 126-40.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.008] [PMID: 27620074]
[30]
Hofland HEJ, van der Geest R, Bodde HE, Junginger HE, Bouwstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharm Res 1994; 11(5): 659-64.
[http://dx.doi.org/10.1023/A:1018963910260] [PMID: 8058633]
[31]
Komatsu H, Higaki K, Okamoto H, Miyagawa K, Hashida M, Sezaki H. Preservative activity and in vivo percutaneous penetration of butylparaben entrapped in liposomes. Chem Pharm Bull 1986; 34(8): 3415-22.
[http://dx.doi.org/10.1248/cpb.34.3415] [PMID: 3791515]
[32]
Brewer J, Bloksgaard M, Kubiak J, Sørensen JA, Bagatolli LA. Spatially resolved two-color diffusion measurements in human skin applied to transdermal liposome penetration. J Invest Dermatol 2013; 133(5): 1260-8.
[http://dx.doi.org/10.1038/jid.2012.461] [PMID: 23223136]
[33]
El Maghraby GMM, Williams AC, Barry BW. Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 2010; 58(4): 415-29.
[http://dx.doi.org/10.1211/jpp.58.4.0001] [PMID: 16597359]
[34]
Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm 1984; 20(1-2): 139-54.
[http://dx.doi.org/10.1016/0378-5173(84)90225-4]
[35]
Kato A, Ishibashi Y, Miyake Y. Effect of egg yolk lecithin on transdermal delivery of bunazosin hydrochloride. J Pharm Pharmacol 2011; 39(5): 399-400.
[http://dx.doi.org/10.1111/j.2042-7158.1987.tb03407.x] [PMID: 2886592]
[36]
Marianecci C, Di Marzio L, Rinaldi F, et al. Niosomes from 80s to present: The state of the art. Adv Colloid Interface Sci 2014; 205: 187-206.
[http://dx.doi.org/10.1016/j.cis.2013.11.018] [PMID: 24369107]
[37]
Verma S, Utreja P. Vesicular nanocarrier based treatment of skin fungal infections: Potential and emerging trends in nanoscale pharmacotherapy. Asian J Pharm Sci 2019; 14(2): 117-29.
[http://dx.doi.org/10.1016/j.ajps.2018.05.007] [PMID: 32104444]
[38]
Chen S, Hanning S, Falconer J, Locke M, Wen J. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm 2019; 144: 18-39.
[http://dx.doi.org/10.1016/j.ejpb.2019.08.015] [PMID: 31446046]
[39]
Yasam VR, Jakki SL, Natarajan J, Kuppusamy G. A review on novel vesicular drug delivery: Proniosomes. Drug Deliv 2014; 21(4): 243-9.
[http://dx.doi.org/10.3109/10717544.2013.841783] [PMID: 24128089]
[40]
Mahajan SS, RY Chaudhari C, VR Patil P. Formulation and evaluation of topical proniosomal gel of ciclopirox for antifungal therapy. Int J Pharm Investig 2021; 11(1): 56-62.
[http://dx.doi.org/10.5530/ijpi.2021.1.11]
[41]
Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release 1998; 54(2): 149-65.
[http://dx.doi.org/10.1016/S0168-3659(97)00100-4] [PMID: 9724902]
[42]
Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta Biomembr 1992; 1104(1): 226-32.
[http://dx.doi.org/10.1016/0005-2736(92)90154-E] [PMID: 1550849]
[43]
Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem 2018; 25(5): 606-35.
[http://dx.doi.org/10.2174/0929867324666171009120154] [PMID: 28990515]
[44]
Das B, Nayak AK, Mallick S. Transferosomes: A novel nanovesicular approach for drug delivery. In: Systems of Nanovesicular Drug Delivery. Academic Press 2022; pp. 103-14.
[45]
Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics 2020; 12(9): 855.
[http://dx.doi.org/10.3390/pharmaceutics12090855] [PMID: 32916782]
[46]
Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: In vitro, ex vivo and in vivo evaluation. Int J Pharm 2017; 527(1-2): 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.029] [PMID: 28522423]
[47]
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes: Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000; 65(3): 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9] [PMID: 10699298]
[48]
Sinico C, Fadda AM. Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv 2009; 6(8): 813-25.
[http://dx.doi.org/10.1517/17425240903071029] [PMID: 19569979]
[49]
Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J Pharm Sci 2017; 106(2): 423-45.
[http://dx.doi.org/10.1016/j.xphs.2016.10.001] [PMID: 27865609]
[50]
Abdulbaqi IM, Darwis Y, Khan NA, Assi RA, Khan AA. Ethosomal nanocarriers: The impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 2016; 11: 2279-304.
[http://dx.doi.org/10.2147/IJN.S105016] [PMID: 27307730]
[51]
Rao BN, Reddy KR, Mounika B, Fathima SR, Tejaswini A. Vesicular drug delivery system: A review. Int J Chemtech Res 2019; 12(5): 39-53.
[http://dx.doi.org/10.20902/IJCTR.2019.120505]
[52]
Hajare A, Dol H, Patil K. Design and development of terbinafine hydrochloride ethosomal gel for enhancement of transdermal delivery: In vitro, in vivo, molecular docking, and stability study. J Drug Deliv Sci Technol 2021; 61: 102280.
[http://dx.doi.org/10.1016/j.jddst.2020.102280]
[53]
Lin B, Wang W, Ba W, Li H, Fan J. Preparation and partial pharmacodynamic studies of luliconazole ethosomes. Clin Exp Pharmacol Physiol 2022; 49(5): 549-57.
[http://dx.doi.org/10.1111/1440-1681.13623] [PMID: 35090058]
[54]
Dave V, Bhardwaj N, Gupta N, Tak K. Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine. 3 Biotech 2020; 10(3): 97.
[55]
Shaji J. In Transethosomes: A new prospect for enhanced transdermal delivery. Int J Pharm Sci 2018; 9(7): 2681-5.
[56]
Bajaj KJ, Parab BS, Shidhaye SS. Nano-transethosomes: A novel tool for drug delivery through skin. Indian J Pharm Educ Res 2021; 55: 1-10.
[57]
Mishra KK, Kaur CD, Gupta A. Development of itraconazole loaded ultra-deformable transethosomes containing oleic-acid for effective treatment of dermatophytosis: Box-Behnken design, ex vivo and in vivo studies. J Drug Deliv Sci Technol 2022; 67: 102998.
[http://dx.doi.org/10.1016/j.jddst.2021.102998]
[58]
Verma S, Utreja P. Transethosomes of econazole nitrate for transdermal delivery: Development, in vitro characterization, and ex vivo assessment. Pharm Nanotechnol 2018; 6(3): 171-9.
[http://dx.doi.org/10.2174/2211738506666180813122102] [PMID: 30101725]
[59]
Ahmed TA, Alzahrani MM, Sirwi A, Alhakamy NA. Study the antifungal and ocular permeation of ketoconazole from ophthalmic formulations containing trans-ethosomes nanoparticles. Pharmaceutics 2021; 13(2): 151.
[http://dx.doi.org/10.3390/pharmaceutics13020151] [PMID: 33498849]
[60]
Patel DM, Patel CN, Jani RH. Ufasomes: A vesicular drug delivery. Sys Rev Pharm 2011; 2(2): 72-8.
[http://dx.doi.org/10.4103/0975-8453.86290]
[61]
Bhattacharya S. Preparation and characterizations of glyceryl oleate ufasomes of terbinafine hydrochloride: A novel approach to trigger Candida albicans fungal infection. Future J Pharm Sci 2021; 7(1): 3.
[http://dx.doi.org/10.1186/s43094-020-00143-w]
[62]
Khalifa MKA. Miconazole Nitrate based cubosome hydrogels for topical application. Int J Drug Deliv 2015; 7: 1-12.
[63]
Alam MM, Aramaki K. Effect of molecular weight of triglycerides on the formation and rheological behavior of cubic and hexagonal phase based gel emulsions. J Colloid Interface Sci 2009; 336(1): 329-34.
[http://dx.doi.org/10.1016/j.jcis.2009.03.054] [PMID: 19394623]
[64]
Lee K, Nguyen T, Hanley T, Boyd B. Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. Int J Pharm 2009; 365(1-2): 190-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.08.022] [PMID: 18790030]
[65]
Rosenblatt KM, Douroumis D, Bunjes H. Drug release from differently structured monoolein/poloxamer nanodispersions studied with differential pulse polarography and ultrafiltration at low pressure. J Pharm Sci 2007; 96(6): 1564-75.
[http://dx.doi.org/10.1002/jps.20808] [PMID: 17094136]
[66]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[67]
Alam MM, Ushiyama K, Aramaki K. Phase behavior, formation, and rheology of cubic phase and related gel emulsion in Tween 80/water/oil systems. J Oleo Sci 2009; 58(7): 361-7.
[http://dx.doi.org/10.5650/jos.58.361] [PMID: 19491531]
[68]
Pan X, Han K, Peng X, et al. Nanostructured cubosomes as advanced drug delivery system. Curr Pharm Des 2013; 19(35): 6290-7.
[http://dx.doi.org/10.2174/1381612811319350006] [PMID: 23470001]
[69]
Rapalli VK, Banerjee S, Khan S, et al. QbD-driven formulation development and evaluation of topical hydrogel containing ketoconazole loaded cubosomes. Mater Sci Eng C 2021; 119: 111548.
[http://dx.doi.org/10.1016/j.msec.2020.111548] [PMID: 33321612]
[70]
Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm 2011; 406(1-2): 163-72.
[http://dx.doi.org/10.1016/j.ijpharm.2010.12.036] [PMID: 21219990]
[71]
Guimarães KL, Ré MI. Lipid nanoparticles as carriers for cosmetic ingredients: The First (SLN) and the Second Generation (NLC). Nanocosmetics and Nanomedicines: New Approaches for Skin Care. Berlin, Heidelberg: Springer Berlin Heidelberg 2011; pp. 101-22.
[http://dx.doi.org/10.1007/978-3-642-19792-5_5]
[72]
Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): Present state of development and industrial applications. Curr Drug Discov Technol 2011; 8(3): 207-27.
[http://dx.doi.org/10.2174/157016311796799062] [PMID: 21291409]
[73]
Battaglia L, Gallarate M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012; 9(5): 497-508.
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[74]
Shrestha H, Bala R, Arora S. Lipid-based drug delivery systems. J Pharm 2014; 2014: 1-10.
[http://dx.doi.org/10.1155/2014/801820] [PMID: 26556202]
[75]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[76]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[77]
del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MÁ. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013; 29(2): 173-88.
[http://dx.doi.org/10.1089/jop.2012.0128] [PMID: 23286300]
[78]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[79]
Gratieri T, Krawczyk-Santos AP, da Rocha PBR, et al. SLN- and NLC-encapsulating antifungal agents: Skin drug delivery and their unexplored potential for treating onychomycosis. Curr Pharm Des 2017; 23(43): 6684-95.
[PMID: 29141535]
[80]
Mahmoud RA, Hussein AK, Nasef GA, Mansour HF. Oxiconazole nitrate solid lipid nanoparticles: Formulation, in vitro characterization and clinical assessment of an analogous loaded carbopol gel. Drug Dev Ind Pharm 2020; 46(5): 706-16.
[http://dx.doi.org/10.1080/03639045.2020.1752707] [PMID: 32266837]
[81]
Elkomy MH, Elmowafy M, Shalaby K, et al. Development and machine-learning optimization of mucoadhesive nanostructured lipid carriers loaded with fluconazole for treatment of oral candidiasis. Drug Dev Ind Pharm 2021; 47(2): 246-58.
[http://dx.doi.org/10.1080/03639045.2020.1871005] [PMID: 33416006]
[82]
Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 2018; 133: 285-308.
[http://dx.doi.org/10.1016/j.ejpb.2018.10.017] [PMID: 30463794]
[83]
Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014; 10: 95-105.
[http://dx.doi.org/10.2147/TCRM.S40160] [PMID: 24611015]
[84]
Danielsson I, Lindman B. The definition of microemulsion. Colloids Surf 1981; 3(4): 391-2.
[http://dx.doi.org/10.1016/0166-6622(81)80064-9]
[85]
Friberg S, Mandell L, Larsson M. Mesomorphous phases, a factor of importance for the properties of emulsions. J Colloid Interface Sci 1969; 29(1): 155-6.
[http://dx.doi.org/10.1016/0021-9797(69)90357-9]
[86]
Sjöblom J, Lindberg R, Friberg SE. Microemulsions: Phase equilibria characterization, structures, applications and chemical reactions. Adv Colloid Interface Sci 1996; 65: 125-287.
[http://dx.doi.org/10.1016/0001-8686(96)00293-X]
[87]
Alexander A, Patel RJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release 2016; 241: 110-24.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.017] [PMID: 27663228]
[88]
Shinoda K, Lindman B. Organized surfactant systems: Microemulsions. Langmuir 1987; 3(2): 135-49.
[http://dx.doi.org/10.1021/la00074a001]
[89]
Lagourette B, Peyrelasse J, Boned C, Clausse M. Percolative conduction in microemulsion type systems. Nature 1979; 281(5726): 60-2.
[http://dx.doi.org/10.1038/281060b0]
[90]
Agrawal M, Saraf S, Saraf S, et al. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opin Drug Deliv 2018; 15(6): 589-617.
[http://dx.doi.org/10.1080/17425247.2018.1471058] [PMID: 29733231]
[91]
Chiappisi L, Noirez L, Gradzielski M. A journey through the phase diagram of a pharmaceutically relevant microemulsion system. J Colloid Interface Sci 2016; 473: 52-9.
[http://dx.doi.org/10.1016/j.jcis.2016.03.064] [PMID: 27054766]
[92]
Shah RM, Eldridge DS, Palombo EA, Harding IH. Microwave-assisted microemulsion technique for production of miconazole nitrate- and econazole nitrate-loaded solid lipid nanoparticles. Eur J Pharm Biopharm 2017; 117: 141-50.
[http://dx.doi.org/10.1016/j.ejpb.2017.04.007] [PMID: 28411057]
[93]
Gradzielski M. Recent developments in the characterisation of microemulsions. Curr Opin Colloid Interface Sci 2008; 13(4): 263-9.
[http://dx.doi.org/10.1016/j.cocis.2007.10.006]
[94]
López-Quintela MA. Synthesis of nanomaterials in microemulsions: Formation mechanisms and growth control. Curr Opin Colloid Interface Sci 2003; 8(2): 137-44.
[http://dx.doi.org/10.1016/S1359-0294(03)00019-0]
[95]
Hoar TP, Schulman JH. Transparent water-in-oil dispersions: The oleopathic hydro-micelle. Nature 1943; 152(3847): 102-3.
[http://dx.doi.org/10.1038/152102a0]
[96]
Oliveira AG, Scarpa MV, Correa MA, Cera LFR, Formariz TP. Microemulsões: Estrutura e aplicações como sistema de liberação de fármacos. Quim Nova 2004; 27(1): 131-8.
[http://dx.doi.org/10.1590/S0100-40422004000100023]
[97]
Mishra R, Prabhavalkar KS, Bhatt LK. Preparation, optimization, and evaluation of Zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery. J Liposome Res 2016; 26(4): 297-306.
[http://dx.doi.org/10.3109/08982104.2015.1120746] [PMID: 26785055]
[98]
Cao M, Ren L, Chen G. Formulation optimization and ex vivo and in vivo evaluation of celecoxib microemulsion-based gel for transdermal delivery. AAPS PharmSciTech 2017; 18(6): 1960-71.
[http://dx.doi.org/10.1208/s12249-016-0667-z] [PMID: 27914040]
[99]
Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: A ubiquitous neglected skin disease. Lancet Infect Dis 2006; 6(12): 769-79.
[http://dx.doi.org/10.1016/S1473-3099(06)70654-5] [PMID: 17123897]
[100]
Gupta N, Gupta G, Siingh D. Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Front Nanotechnol 2022; 4: 10006628.
[101]
Talaat SM, Elnaggar YSR, Abdalla OY. Lecithin microemulsion lipogels versus conventional gels for skin targeting of terconazole: In vitro, ex vivo, and in vivo investigation. AAPS PharmSciTech 2019; 20(4): 161.
[http://dx.doi.org/10.1208/s12249-019-1374-3] [PMID: 30969396]
[102]
Thacharodi D, Panduranga RK. Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers. Int J Pharm 1994; 111(3): 235-40.
[http://dx.doi.org/10.1016/0378-5173(94)90346-8]
[103]
Abdellatif MM, Khalil IA, Elakkad YE, Eliwa HA, Samir T, Al-Mokaddem AK. Formulation and characterization of sertaconazole nitrate mucoadhesive liposomes for vaginal candidiasis. Int J Nanomedicine 2020; 15: 4079-90.
[http://dx.doi.org/10.2147/IJN.S250960] [PMID: 32606665]
[104]
Zhang L, Li X, Zhu S, et al. Dermal targeting delivery of terbinafine hydrochloride using novel multi-ethosomes: A new approach to fungal infection treatment. Coatings 2020; 10(4): 304.
[http://dx.doi.org/10.3390/coatings10040304]
[105]
Singh AK, Mukerjee A, Pandey H, Mishra SB. Miconazole nitrate–loaded solid lipid nanoparticle-based hydrogel ameliorate Candida albicans induced mycoses in experimental animals. Bionanoscience 2022; 12(2): 512-26.
[http://dx.doi.org/10.1007/s12668-022-00948-4]
[106]
Carbone C, Fuochi V, Zielińska A, et al. Dual-drugs delivery in solid lipid nanoparticles for the treatment of Candida albicans mycosis. Colloids Surf B Biointerfaces 2020; 186: 110705.
[http://dx.doi.org/10.1016/j.colsurfb.2019.110705] [PMID: 31830707]
[107]
Sharma M, Mundlia J, Kumar T, Ahuja M. A novel microwave-assisted synthesis, characterization and evaluation of luliconazole-loaded solid lipid nanoparticles. Polym Bull 2021; 78(5): 2553-67.
[http://dx.doi.org/10.1007/s00289-020-03220-5]
[108]
Waghule T, Rapalli VK, Singhvi G, et al. Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in vitro and ex vivo evaluation. J Drug Deliv Sci Technol 2019; 52: 303-15.
[http://dx.doi.org/10.1016/j.jddst.2019.04.026]
[109]
Singh S, Singh M, Tripathi CB, Arya M, Saraf SA. Development and evaluation of ultra-small nanostructured lipid carriers: Novel topical delivery system for athlete’s foot. Drug Deliv Transl Res 2016; 6(1): 38-47.
[http://dx.doi.org/10.1007/s13346-015-0263-x] [PMID: 26542152]
[110]
Baghel S, Nair VS, Pirani A, et al. Luliconazole‐loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections. Dermatol Ther 2020; 33(6): e13959.
[http://dx.doi.org/10.1111/dth.13959] [PMID: 32618400]
[111]
Zafar A, Qumber M, Alruwaili N, et al. BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: In vitro evaluation and antimicrobial assessment. J Pharm Innov 2020; 16: 85-98.
[112]
Ferreira PG, Noronha L, Teixeira R, et al. Investigation of a microemulsion containing clotrimazole and itraconazole for transdermal delivery for the treatment of sporotrichosis. J Pharm Sci 2020; 109(2): 1026-34.
[http://dx.doi.org/10.1016/j.xphs.2019.10.009] [PMID: 31604084]
[113]
Samy A, Ramadan AA, El-enin ASMA, Yasmin I. In novel proniosomes as drug delivery system for transdermal application of itraconazole:Development, Characterization, clinical and bioavailability study. J Pharm Biol Sci 2018; 13(1): 54-71.
[114]
Yang Q, Liu S, Gu Y, et al. Development of sulconazole-loaded nanoemulsions for enhancement of transdermal permeation and antifungal activity. Int J Nanomedicine 2019; 14: 3955-66.
[http://dx.doi.org/10.2147/IJN.S206657] [PMID: 31239665]
[115]
Clinical Trial Gov. Clinical assessment of voriconazole self nano emulsifying drug delivery system intermediate gel. Available at: https://clinicaltrials.gov/ct2/show/NCT04110860?term=voriconazole%2C+self+nano+emulsifying&draw=2&rank=1 (accessed 04-11-2022).
[116]
Clinical Trial Gov. Clinical assessment of itraconazole self nano emulsifying drug delivery system intermediate gel. Available at: https://clinicaltrials.gov/ct2/show/NCT04110834?term=nct04110834&draw=2&rank=1 (accessed 04-11-2022).
[117]
Clinical Trial Gov. TDT 067 onychomycosis study. tdt 067 onychomycosis study. Available at: https://clinicaltrials.gov/ct2/show/NCT01145807 (accessed 04-11- 2022).
[118]
Clinical Trial Gov. Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03823040 (accessed 04-11-2022).
[119]
El-Housiny S, Shams Eldeen MA, El-Attar YA, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: Formulation and clinical study. Drug Deliv 2018; 25(1): 78-90.
[http://dx.doi.org/10.1080/10717544.2017.1413444] [PMID: 29239242]
[120]
Lamie C, Elmowafy E, Ragaie MH, Attia DA, Mortada ND. Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: Comparative clinical study. Drug Deliv 2022; 29(1): 1345-57.
[http://dx.doi.org/10.1080/10717544.2022.2067601] [PMID: 35506466]
[121]
Albash R, Ragaie MH, Hassab MAE, et al. Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis: Design characterization, in silico study, and exploratory clinical appraisal. Drug Deliv 2022; 29(1): 1100-11.
[http://dx.doi.org/10.1080/10717544.2022.2057619] [PMID: 35373684]
[122]
ClinicalTrials.gov. Adjunctive Sertraline for the Treatment of HIVAssociated Cryptococcal Meningitis. Available at: https://clinicaltrials.gov/ct2/show/NCT01802385
[123]
ClinicalTrials.gov. Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis. Available at: https://clinicaltrials.gov/ct2/show/NCT03471988
[124]
ClinicalTrials.gov. Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120). Available at: https://clinicaltrials.gov/ct2/show/NCT03336502
[125]
ClinicalTrials.gov. Endemic Mycoses Treatment With SUBAitraconazole vs Itraconazole (MSG15). Available at: https://clinicaltrials.gov/ct2/show/NCT03572049
[126]
ClinicalTrials.gov. Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses. Available at: https://clinicaltrials.gov/ct2/show/NCT00722189
[127]
Young-wook Choi, Chil-hwan Oh, Kyung-ho Kang, et al. Cell penetrating peptide modified nanoliposome and anti-atopic composition comprising the same. KP 101130550B1, 2012.
[128]
Orza A. Method for preparing ph dependent ultra small polymeric nanoparticles for topical and/or transdermal delivery. US 10850246B2, 2020.
[129]
Gary Van Nest ST, Karen L. Dino Dina Biodegradable immunomodulatory formulations and methods for use there of. US 8669237B2, 2014.
[130]
Anita Shukla SC. Eli silvert antifungal nanoparticles for targeted treatment of fungal infections. US 011273124B2, 2022.
[131]
Stephen W. Antimicrobial and antifungal polymer fibers, fabrics, and methods of manufacture thereof. US 010508188B2, 2019.
[132]
Chariou PL, Ortega-Rivera OA, Steinmetz NF. Nanocarriers for the delivery of medical, veterinary, and agricultural active ingredients. ACS Nano 2020; 14(3): 2678-701.
[http://dx.doi.org/10.1021/acsnano.0c00173] [PMID: 32125825]
[133]
Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017; 9(1): e1416.
[http://dx.doi.org/10.1002/wnan.1416] [PMID: 27312983]
[134]
Shen J, Burgess DJ. In vitro dissolution testing strategies for nanoparticulate drug delivery systems: Recent developments and challenges. Drug Deliv Transl Res 2013; 3(5): 409-15.
[http://dx.doi.org/10.1007/s13346-013-0129-z] [PMID: 24069580]
[135]
Larsson S, Jansson M, Boholm Å. Expert stakeholders’ perception of nanotechnology: Risk, benefit, knowledge, and regulation. J Nanopart Res 2019; 21(3): 57.
[http://dx.doi.org/10.1007/s11051-019-4498-1]
[136]
Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001; 18(5): 26.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v18.i5.10] [PMID: 11763497]
[137]
Maroni A, Zema L, Curto MDD, Loreti G, Gazzaniga A. Oral pulsatile delivery: Rationale and chronopharmaceutical formulations. Int J Pharm 2010; 398(1-2): 1-8.
[http://dx.doi.org/10.1016/j.ijpharm.2010.07.026] [PMID: 20655998]
[138]
Staples M, Daniel K, Cima MJ, Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm Res 2006; 23(5): 847-63.
[http://dx.doi.org/10.1007/s11095-006-9906-4] [PMID: 16715375]
[139]
Sutradhar KB, Sumi CD. Implantable microchip: The futuristic controlled drug delivery system. Drug Deliv 2016; 23(1): 1-11.
[http://dx.doi.org/10.3109/10717544.2014.903579] [PMID: 24758139]
[140]
Wang W, Ye Z, Gao H, Ouyang D. Computational pharmaceutics: A new paradigm of drug delivery. J Control Release 2021; 338: 119-36.
[http://dx.doi.org/10.1016/j.jconrel.2021.08.030] [PMID: 34418520]
[141]
Han R, Xiong H, Ye Z, et al. Predicting physical stability of solid dispersions by machine learning techniques. J Control Release 2019; 311-312: 16-25.
[http://dx.doi.org/10.1016/j.jconrel.2019.08.030] [PMID: 31465824]
[142]
Thota N, Jiang J. Computat cional amphiphilic materials for drug delivery. Front Mater 2015; 2: 64.
[143]
Huynh L, Neale C, Pomès R, Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine 2012; 8(1): 20-36.
[http://dx.doi.org/10.1016/j.nano.2011.05.006] [PMID: 21669300]
[144]
He Y, Ye Z, Liu X, et al. Can machine learning predict drug nanocrystals? J Control Release 2020; 322: 274-85.
[http://dx.doi.org/10.1016/j.jconrel.2020.03.043] [PMID: 32234511]
[145]
Egorov E, Pieters C, Korach-Rechtman H, Shklover J, Schroeder A. Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems. Drug Deliv Transl Res 2021; 11(2): 345-52.
[http://dx.doi.org/10.1007/s13346-021-00929-2] [PMID: 33585972]
[146]
Duarte Y, Márquez-Miranda V, Miossec MJ, González-Nilo F. Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019; 11(4): e1554.
[http://dx.doi.org/10.1002/wnan.1554] [PMID: 30932351]
[147]
Maas J, Kamm W, Hauck G. An integrated early formulation strategy: From hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 2007; 66(1): 1-10.
[http://dx.doi.org/10.1016/j.ejpb.2006.09.011] [PMID: 17123801]
[148]
Gonzalez-Ibanez AM, Gonzalez-Nilo F, Cachau R. The collaboratory for structural nanobiology. Biophys J 2009; 96(3): 49a.
[http://dx.doi.org/10.1016/j.bpj.2008.12.151]
[149]
Ostraat ML, Mills KC, Guzan KA, Murry D. The nanomaterial registry: Facilitating the sharing and analysis of data in the diverse nanomaterial community. Int J Nanomedicine 2013; 8(1): 7-13.
[PMID: 24098075]

Rights & Permissions Print Cite
Article Metrics
32
2
Wayfinder Image
© 2025 Bentham Science Publishers | Privacy Policy